As of Jun 29
| -2.53 / -3.60%|
The 9 analysts offering 12-month price forecasts for Pacira Pharmaceuticals Inc have a median target of 92.00, with a high estimate of 116.00 and a low estimate of 70.00. The median estimate represents a +35.79% increase from the last price of 67.75.
The current consensus among 9 polled investment analysts is to Buy stock in Pacira Pharmaceuticals Inc. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.